Linagliptin-A novel dipeptidyl peptidase inhibitor for type 2 diabetes therapy

Clinical Medicine Insights: Endocrinology and Diabetes

Volumn 5, Issue , 2012, Pages

  Gallwitz, Baptist ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

DPP 4 inhibitors; Incretin based therapies; Linagliptin; Oral antidiabetics; Type 2 diabetes

Indexed keywords

DIGOXIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INSULIN; LINAGLIPTIN; METFORMIN; PIOGLITAZONE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; VOGLIBOSE;

ADD ON THERAPY; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; BIOEQUIVALENCE; BLOOD DISEASE; CARDIOVASCULAR SYMPTOM; COMBINATION CHEMOTHERAPY; COUGHING; CREATINE KINASE BLOOD LEVEL; DOSAGE SCHEDULE COMPARISON; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FATTY LIVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; IC 50; LABORATORY TEST; LYMPHATIC SYSTEM DISEASE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PLEIOTROPY; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXIC HEPATITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84857022997     PISSN: 11795514     EISSN: 11795514     Source Type: Journal    
DOI: 10.4137/CMED.S7274     Document Type: Review

References (41)

1. International Diabetes Federation (IDF): diabetes atlas. 2009. Available from: http://www.diabetesatlas.org.
2. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-705.
3. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986;63:492-8.
4. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfedt W. Normalization of fasting hyperglycaemia by exogenousglucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:741-4.
5. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214:829-35.
6. Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes. 1998;47:764-9.
7. Ahrén B, Simonsson E, Larsson H, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care. 2002;25:869-75.
8. Gallwitz B. Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update). Drugs Today (Barc). 2007;43:801-14.
9. Gallwitz B. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes. Drugs Today (Barc). 2007;43:681-9.
10. German Diabetes Association, Matthaei S, Bierwirth R, et al. Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the german diabetes association. Exp Clin Endocrinol Diabetes. 2009;117:522-57.
11. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin- 2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI1356), a novel xanthinebased dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther. 2008;325:175-82.
12. Eckhardt M, Hauel N, Himmelsbach F, et al. 3,5-Dihydro-imidazo[4,5-d] pyridazin-4-ones: a class of potent DPP-4 inhibitors. Bioorg Med Chem Lett. 2008;18:3158-62.
13. Gallwitz B. Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy. Exp Opin Invest Drugs. 2011;20:723-32.
14. Eckhardt M, Langkopf E, Mark M, et al. 8-(3-(R)-aminopiperidin-1-yl)-7- but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydropurine- 2,6-dione (BI1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem. 2007;50:6450-3.
15. Fuchs H, Binder R, Greischel A. Tissue distribution of the novel DPP-4 inhibitor BI1356 is dominated by saturable binding to its target in rats. Biopharm Drug Dispos. 2009;30:229-40.
16. Fuchs H, Tillement JP, Urien S, Greischel A, Roth W. Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI1356 due to saturable binding to its target in plasma of mice, rats and humans. J Pharm Pharmacol. 2009;61:55-62.
17. Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2010;19:133-40.
18. Herman GA, Stein PP, Thornberry NA, Wagner JA. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther. 2007;81:761-7.
19. He YL, Sadler BM, Sabo R, et al. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase- IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet. 2007;46:787-802.
20. Huttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol. 2008;48:1171-8.
21. Heise T, Graefe-Mody EU, Hüttner S, Ring A, Trommeshauser D, Dugi KA. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab. 2009;11:786-94.
22. Horie Y, Kanada S, Watada H, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients. Clin Ther. 2011;33: 973-89.
23. Graefe-Mody EU, Padula S, Ring A, Withopf B, Dugi KA. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin. 2009;25:1963-72.
24. Graefe-Mody EU, Jungnik A, Ring A, Woerle HJ, Dugi KA. Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers. Int J Clin Pharmacol Ther. 2010;48:652-61.
25. Friedrich C, Ring A, Brand T, Sennewald R, Graefe-Mody EU, Woerle HJ. Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. Eur J Drug Metab Pharmacokinet. 2011;36:17-24.
26. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptinmonotherapy on glycaemic control and markers of â-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011;13: 258-67.
27. Horie Y, Hayashi N, Dugi K, Takeuchi M. Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo. Trials. 2009;10:82.
28. Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13:65-74.
29. Haak T, Meinicke T, Russell-Jones DL, von Eynatten M, Woerle HJ. Combination of linagliptin and metformin improves glycemic control in type 2 diabetes: a randomized trial with an open-label arm in patients with poor glycemic control. Diabetes. 2011;60 Suppl 1:279 OR.
30. Gallwitz B, Uhlig-Laske B, Bhattacharaya SP, Woerle HJ. Linagliptin Has Similar Efficacy to Glimepiride but Improved Cardiovascular Safety over 2 years in patients with type 2 diabetes inadequately controlled on metformin. Diabetes. 2011;60 Suppl 1:39-LB.
31. Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13: 653-61.
32. Graefe-Mody U, Rose P, Ring A, Zander K, Iovino M, Woerle HJ. Pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects. Drug Metab Pharmacokinet. 2011;26:123-9.
33. Friedrich C, Metzmann K, Rose P, Mattheus M, Pinnetti S, Woerle JH. Pharmacokinetics and pharmacodynamics of BI10773, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, following co-administration in healthy volunteers. Diabetes. 2011;60 Suppl 1:2327-PO.
34. Schernthaner G, von Eynatten M, Emser A, Patel S, Woerle HJ. Safety and tolerability of linagliptin: A pooled analysis of data from 3572 patients with type 2 diabetes. Diabetes. 2011;60 Suppl 1:2327-PO.
35. Schürmann C, Frank S, Greischel A, Mark M, Klein T. Linagliptin functionally counteracts a dysregulation in DPP-4 expression in diabetes-impaired wounds. Diabetes. 2010;59 Suppl 1:576-P.
36. Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci. 2009;30:600-7.
37. Klein T, Batra A, Mark M, Siegmund B. The DPP-4 inhibitor linagliptin increases active GLP-2 and decreases colonic cytokines in a mouse inflammatory bowel disease model. Diabetes. 2011;60 Suppl 1:1124-P.
38. Klein T, Niessen H, Thomas L, Stiller D, Mark M. Linagliptin improves hepatic steatosis in rodent models: a magnetic resonance spectroscopy based study. Diabetes. 2010;59 Suppl 1:577-P.
39. Pfab T, Sharkovska Y, Alter M, et al. Effect of linagliptin on infarction size and cardiac function in rats after myocardial ischaemia reperfusion. Diabetologia. 2011;54 Suppl 1:A 811.
40. Kalra S, Unnikrishnan AG, Agrawal N, Singh AK. Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications. Recent Pat Endocr Metab Immune Drug Discov. 2011;5:197-202.
41. Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ. Cardiovascular risk with linagliptin in patients with type 2 diabetes: a prespecified, prospective, and adjudicated meta-analysis from a large phase III program. Diabetes. 2011;60 Suppl 1:30-LB.